This article identifies four key processing technologies that are utilized by cord blood banks worldwide and the companies responsible for developing each one. Automated processing systems have many benefits, including speed, processing efficiency, and cost-savings. However, automated processing systems have not always dominated the cord blood banking industry.
Cord Blood
Because cord blood present within a newborn’s umbilical is rich with stem cells, it can be collected and stored for future medical use.
Porton Advanced’s UC-MSCs Cell Bank for Exosome Manufacturing Receives U.S. FDA Drug Master File (DMF) Acceptance
CRANBURY, N.J. and SUZHOU, China, July 8, 2026 — Recently, Porton Advanced proudly announced that its Umbilical Cord-Derived Mesenchymal Stem Cell (UC-MSCs) Cell Bank for exosome manufacturing has been accepted for filing by the FDA’s Center for Biologics Evaluation and Research (CBER), under Drug Master File (DMF) #32973.
This milestone further strengthens Porton Advanced’s position in the rapidly evolving exosome therapeutics market. With the DMF filing, sponsors advancing exosome programs can reference DMF #32973 in their own regulatory submissions, significantly accelerating U.S. FDA review pathways and reducing duplicative documentation. [Read more…]
MEDIPOST Inc. Treats First U.S. Participant in Phase III Trial of Umbilical Cord Stem Cell Therapy for Knee Osteoarthritis
U.S. Phase III Trial Expands Clinical Investigation of Stem Cell Therapy for Knee Cartilage Defects
CAMBRIDGE, Mass.–MEDIPOST Inc., a biotechnology company developing allogeneic, umbilical cord blood-derived stem cell therapies for inflammation-driven degenerative diseases, announced today the treatment of the first U.S. participant in its Phase III clinical trial evaluating its investigational mesenchymal stem cell (MSC) therapy to treat symptomatic cartilage defects in adults with knee osteoarthritis. The FDA has agreed that this single pivotal study, supported by confirmatory evidence from prior Phase 3 trials in South Korea and Japan together with Korean real-world evidence, can serve as the basis for MEDIPOST’s planned U.S. BLA filing. The milestone marks a significant step forward in MEDIPOST’s mission to bring a first-of-its-kind regenerative therapy to patients in the United States. This procedure was performed by Dr. Justin Newman at Orthopedic Centers of Colorado. [Read more…]
Anja Health Expands Partnership with Vitalant Cord Blood Stem Cell Laboratory to Advance Newborn Stem Cell Preservation
More Than 100 Years of Combined Experience Supporting Families and the Future of Regenerative Medicine
LOS ANGELES, CA, UNITED STATES, June 16, 2026 — Anja Health, a leading provider of newborn stem cell preservation services, announced the expansion of its partnership with the Vitalant Cord Blood Stem Cell Laboratory, one of the nation’s most respected stem cell processing and storage facilities, further strengthening Anja Health’s commitment to providing families with advanced cord blood, cord tissue, and placenta stem cell preservation services. [Read more…]
Cord for Life® Completes the First Clinical Trial Using Cord Blood Stem Cells for a Non-Transplant Medical Treatment of Lower Back Pain
ALTAMONTE SPRINGS, Fla. — In a historical moment for umbilical cord blood stem cell research, Cord for Life®, Inc. announces the completion of phase 1 of a clinical trial for lower back pain treatment. This marks the first time umbilical cord blood stem cells have been evaluated for a treatment not related to transplantation and regeneration of the recipient’s bone marrow to generate new blood cells. This early success could lead to numerous other trials for a wide range of treatments that could have a significant effect on the quality of life for tens of millions of patients worldwide. [Read more…]
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 62
- Next Page »